Rosen Law Firm reminds purchasers of GRAIL common stock between May 13, 2025 and February 19, 2026 of the August 4, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that defendants made materially false and misleading statements and concealed adverse facts about the NHS-Galleri trial, including that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers and that detailed topline results were withheld. Investors who purchased shares during the class period may be entitled to compensation through a contingency fee arrangement without out-of-pocket costs. A lead plaintiff must move the Court by August 4, 2026.
GRAIL, LLCSecurities class action lawsuit alleging false statements about NHS-Galleri trial results and withheld adverse facts.